CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics - read this article along with other careers information, tips and advice on BioSpace
09.01.2023 - Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson’s disease (PD)The Rostock International Parkinson s Disease (ROPAD) Study aims to . Seite 1
Published: Mar 09, 2021
Rostock International Parkinson s Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment
Significant milestone of 10,000 participants reached
With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinson’s disease ever performed
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a significant milestone in its Rostock International Parkinson s Disease (ROPAD) Study, with the recruitment and genetic testing of 10,000 participants. Including more than 120 study sites around the world, CENTOGENE is leading the largest study of its kin
CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study
March 09, 2021 06:30 ET | Source: CENTOGENE GmbH CENTOGENE GmbH Rostock, GERMANY
Rostock International Parkinson s Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment
Significant milestone of 10,000 participants reached
With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinson’s disease ever performed
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a significant milestone in its Rostock International Parkinson